首页> 美国卫生研究院文献>Gynecologic Oncology Reports >Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

【2h】

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

机译：曲妥珠单抗（TDM-1）过度表达HER2 / neu的转移性，放射线/化疗耐药性子宫浆液性癌的消退

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundThe management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed.

机译：背景子宫浆液性癌（USC）的治疗不再适合通过手术，放疗和/或化学疗法进行治疗。迫切需要替代治疗选择。

著录项

期刊名称 Gynecologic Oncology Reports
作者
Alessandro D. Santin; Stefania Bellone; Natalia Buza; Peter E. Schwartz;
展开▼
作者单位

展开▼
年(卷),期 2006(19),
年度 2006
页码 10–12
总页数 3
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Uterine serous carcinoma, Trastuzumab-emtansine, HER2/neu;

机译：子宫浆液性癌;曲妥珠单抗-丹参碱;HER2 / neu;

相似文献

外文文献
中文文献
专利

1. Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2eu with trastuzumab emtansine (TDM-1) [J] . Alessandro D. Santin, Stefania Bellone, Natalia Buza, Gynecologic Oncology Reports . 2017,第1期

机译：曲妥珠单抗Emtansine（TDM-1）过度表达HER2 / neu的转移性，放射线/化疗耐药性子宫浆液性癌的消退
2. Randomized Phase II Trial of Carboplatin–Paclitaxel Compared with Carboplatin–Paclitaxel–Trastuzumab in Advanced (Stage III–IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis [J] . Amanda N. Fader, Dana M. Roque, Eric Siegel, Clinical cancer research: an official journal of the American Association for Cancer Research . 2020,第15期

机译：Carboplatin-PAClitaxel的随机期II试验与晚期（IIII-IV）或经复制的子宫浆液癌的Carboplatin-PACLitaxel-Trastuzumab（NCT01367002）：更新总存活分析
3. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2|[sol]|neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy [J] . S Bellone, D Roque, E Cocco, British Journal of Cancer . 2012,第9期

机译：siRNA下调膜补体抑制剂CD55和CD59使子宫浆液性癌过表达Her2 | [sol] | neu对补体和抗体依赖性细胞的体外细胞毒性敏感：对基于曲妥珠单抗的免疫治疗的意义
4. Whole-body imaging of HER2/neu-overexpressing tumors usingscFv-antibody conjugated quantum dots [C] . Irina V. Balalaeva, Tatyana A. Zdobnova, Anna A. Brilkina, SPIE Conference on Colloidal Quantum Dots for Biomedical Applications . 2010

机译：HER2 / Neu过表达肿瘤的全身成像USINGSCFV-抗体共轭量子点
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma [O] . Silvia Pelligra, Natalia Buza, Pei Hui, 2020

机译：选择HER2 / NEU阴性肿瘤细胞作为子宫浆液癌患者抗曲妥珠单抗的机制
7. Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1) [O] . Alessandro D. Santin, Stefania Bellone, Natalia Buza, 2017

机译：用曲妥珠单抗emtansine（TDm-1）过表达HER2 / neu的转移性，放射/化疗耐药的子宫浆液性癌的回归
8. Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide- Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy; Annual rept. 27 Apr 2007-26 Apr 2008 [R] . Disis, M. L. 2008

机译：对接受曲妥珠单抗单一疗法的IIIB和IV期HER2阳性乳腺癌患者施用HER-2 / neu（HER2）细胞内结构域（ICD）基于肽的疫苗的II期研究;年度报告。 2007年4月27日至2008年4月26日

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

摘要

著录项

相似文献

相关主题

期刊订阅